AcquisitionOther
MannKind Corporation acquired scPharmaceuticals Inc.
Public deal record from 8-K. The source names the buyer and target, and terms are shown only when the filing or announcement discloses them.
Deal tape row
MannKind Corporation -> scPharmaceuticals Inc. · Upfront cash payment of $5.35 per share plus contingent value right (CVR) of up to $1.00 per share
Strategic expansion into cardiorenal medicine with innovative FUROSCIX treatment.
Open source record (SEC) ↗